Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
Vir Biotechnology reported Q1 2026 financial results with a net loss of $0.85 per share and a cash position of $809.3 million, boosted by a recently closed $172.5 million public offering. The company finalized its global collaboration with Astellas for VIR-5500, triggering $315 million in combined payments, and dosed the first patient in Phase 1 dose-expansion cohorts for metastatic prostate cancer.
Key figures
- Guidance
- Cash, cash equivalents and investments to fund operations into the second half of 2028
- Net loss
- 125700000
- Rd expenses
- 108900000
- Cash and investments
- 809300000
- Astellas payment pending
- 315000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.